Next 10 |
home / stock / indp / indp articles
- Chief Scientific Officer Dr. Newman to present initial clinical data that further validates Company's "Pulse-Prime" hypothesis - Dr. Newma...
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pionee...
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pion...
"Fully Engaging The Human Immune System To Cure Disease," Featuring CEO, Jeffrey Meckler Registration now open at INDPMarch2024.TribePublic.com ...
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter fin...
Shares of Okta, Inc. (NASDAQ: OKTA) shares rose sharply in today’s pre-market trading after the company reported better-than-expected fourth...
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock b...
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical biopharma company that utilizes a proprietary ...
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced today that Jeffrey A. Meckler, Chief Executive ...
News, Short Squeeze, Breakout and More Instantly...
Indaptus Therapeutics Inc. Company Name:
INDP Stock Symbol:
NASDAQ Market:
Indaptus Therapeutics Inc. Website:
- Chief Scientific Officer Dr. Newman to present initial clinical data that further validates Company’s “Pulse-Prime” hypothesis - Dr. Newman also named Chair of the Summit NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a...
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its Chief Medical Officer, Roger Waltzman, M.D., will present an update on ...
Latest data from first and second cohorts support Company’s 'pulse-prime' approach, demonstrating rapid clearance, broad immune activation, and encouraging safety profile Poster Presented at American Society of Clinical Oncology Annual Meeting NEW YORK, June 03, 2024 (GLOBE...